Jun 3 • General discussion
Retatrutide? And then there were THREE!
The next generation after Wegovy and Mounjaro
First came the GLP-1 medicines such as semaglutide, better known by brand names including Wegovy and Ozempic.
Then came tirzepatide, known in the UK as Mounjaro, often described as a “TwinCretin” because it acts on two hormone pathways: GIP and GLP-1.
Now there is growing interest in retatrutide — an investigational once-weekly injection that acts on three pathways: GIP, GLP-1 and glucagon.
That is why people are calling it a “triple agonist”
Retatrutide is not yet licensed for routine clinical use. It is still being studied. But the early data are striking, and it may represent the next major step in weight-loss medication.
What makes retatrutide different?
Most current weight-loss injections work largely by helping people eat less.
They reduce hunger. They increase fullness. They reduce cravings. They quieten “food noise”.
That can be extremely helpful.
Retatrutide appears to go further because it adds glucagon receptor activation. Glucagon is often thought of as the hormone that raises blood sugar, but it also has important effects in the liver, including fat oxidation and energy use.
In simple terms:
- semaglutide acts mainly on GLP-1;
- tirzepatide acts on GIP and GLP-1;
- retatrutide acts on GIP, GLP-1 and glucagon.
This may mean retatrutide affects both sides of the equation: not just appetite and food intake, but potentially fat burning, liver fat and energy expenditure too.
How much weight loss has been reported?
In earlier phase 2 studies, higher doses of retatrutide produced average weight loss of around 23–24% over 48 weeks.
More recently, Lilly reported phase 3 topline data from the TRIUMPH-1 trial. At 80 weeks, average weight loss was reported as:
- 19.0% with retatrutide 4 mg;
- 25.9% with retatrutide 9 mg;
- 28.3% with retatrutide 12 mg;
- 2.2% with placebo.
In a longer extension group, average weight loss reportedly reached about 30% at 104 weeks in the highest-dose group.
Those are very large numbers.
But there is an important caveat: these are not yet fully peer-reviewed published phase 3 results, and retatrutide is not yet licensed.
Why this does not replace lifestyle
This is the crucial point.
Even if retatrutide proves to be more powerful than Wegovy or Mounjaro, it still does not solve the whole problem.
Weight-loss injections can reduce appetite. They can reduce food noise. They can make it easier to eat less.
But they do not automatically teach people how to eat well.
They do not preserve muscle unless protein and resistance training are in place.
They do not guarantee long-term maintenance.
They do not remove the risk of weight regain when treatment stops.
They do not replace metabolic health.
That is why the ProLongevity Essentials approach matters.
The drug may create an opportunity. The lifestyle work determines whether that opportunity becomes a lasting result.
The real question is not just “How much weight?”
A lower number on the scales is not enough.
The better questions are:
- Are you losing fat rather than muscle?
- Are you eating enough protein?
- Are you getting stronger or weaker?
- Is your blood glucose improving?
- Is your waist shrinking?
- Is your liver fat improving?
- Are you building habits you can sustain?
- Is there a plan for stopping or reducing medication later?
These questions matter even more as the medicines become more powerful.
A warning about buying retatrutide online
Retatrutide is not currently licensed for routine use.
That means it should not be bought from social media, Telegram groups, “research peptide” websites or unofficial online sellers.
Anything claiming to be retatrutide outside a legitimate clinical trial should be treated as high risk.
The dangers include counterfeit products, wrong dosing, contamination, severe side effects and no medical supervision.
Retatrutide is not a supplement. It is not a gym hack. It is a powerful investigational medicine.
The Essentials view
At ProLongevity Essentials, we are not anti-medication.
Used properly, weight-loss injections can be very helpful.
But we are strongly against the idea that injections alone are the answer.
The real goal is not just weight loss.
The real goal is metabolic health.
That means:
- reducing food noise;
- improving blood glucose;
- protecting muscle;
- eating enough protein;
- reducing ultra-processed food;
- improving energy;
- building habits that last;
- and having a realistic plan for maintenance.
Retatrutide may become the next major obesity drug.
But the lesson is the same as with Wegovy and Mounjaro:
The medicine can open the door. You still have to walk through it.
2
3 comments
Retatrutide? And then there were THREE!
powered by
skool.com/make-your-mark-weight-loss-3193
Mounjaro and GLP-1 support. No extremes. Real experiences, accountability and sustainable weight loss from people who get it.
Suggested communities
Powered by